DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Chronic Rhinosinusitis with Nasal Polyps, historical and forecasted epidemiology as well as the Chronic Rhinosinusitis with Nasal Polyps market trends in the United States, EU4, and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Chronic Rhinosinusitis with Nasal Polyps Market with DelveInsight’s In-Depth Report @ Chronic Rhinosinusitis with Nasal Polyps Market Size

 

Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report

• In November 2024:- AstraZeneca- This is a multicentre, open-label, single-arm, phase IIIb study is to describe changes from baseline in (1) participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) and (2) participant-reported sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) following initiation of tezepelumab treatment.
• In November 2024:- Upstream Bio Inc.- The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placebo.
• In the assessment done by DelveInsight, the estimated total Chronic Rhinosinusitis Prevalent Cases in the 7MM were ~70,188 thousand in 2023.
• The highest total Chronic Rhinosinusitis with Nasal Polyps diagnosed prevalent cases were accounted by the US in 2023 (~2,209 thousand), which is expected to show a rise in the future.
• Among the European countries, Germany had the highest Chronic Rhinosinusitis with Nasal Polyps diagnosed prevalent cases with ~616 thousand cases, followed by the UK, which had diagnosed prevalent population of ~441 thousand in 2023. On the other hand, Spain had the lowest diagnosed prevalent population (~189 thousand cases).
• Japan had ~202 thousand total diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps in 2023, accounting for approximately 5% in 7MM.
• In 2023, in the US, the gender-specific diagnosed prevalent cases of Chronic Rhinosinusitis with Nasal Polyps were highest for males (~55%), as compared to males (~45%), which is attributed to factors such as hormonal differences and physiology, lifestyle and occupational factors and others.
• The leading Chronic Rhinosinusitis with Nasal Polyps Companies such as AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
• Promising Chronic Rhinosinusitis with Nasal Polyps Therapies such as NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others

 

Stay ahead in the Chronic Rhinosinusitis with Nasal Polyps Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Rhinosinusitis with Nasal Polyps Market Outlook

 

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation in the 7MM

• Total Prevalence of Chronic Rhinosinusitis with Nasal Polyps
• Prevalent Cases of Chronic Rhinosinusitis with Nasal Polyps by severity
• Gender-specific Prevalence of Chronic Rhinosinusitis with Nasal Polyps
• Diagnosed Cases of Episodic and Chronic Chronic Rhinosinusitis with Nasal Polyps

 

Download the report to understand which factors are driving Chronic Rhinosinusitis with Nasal Polyps epidemiology trends @ Chronic Rhinosinusitis with Nasal Polyps Prevalence

 

Chronic Rhinosinusitis with Nasal Polyps Marketed Drugs

 

• NUCALA (mepolizumab): GlaxoSmithKline

GSK’s NUCALA (mepolizumab) is the first IL-5 therapy approved as an add-on treatment in the US for adults with CRSwNP to target eosinophilic inflammation in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. The recommended dosage of mepolizumab is 100 mg, administered once every 4 weeks by subcutaneous injection into the upper arm, thigh, or abdomen. Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. By inhibiting IL-5 signaling, mepolizumab reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma, CRSwNP, EGPA, and HES has not been definitively established.

 

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs

 

• TEZSPIRE (tezepelumab): AstraZeneca/Amgen

TEZSPIRE (tezepelumab) is a potential human monoclonal antibody (immunoglobulin [Ig] G2λ) that inhibits the action of thymic stromal lymphopoietin (TSLP). TSLP expression is elevated in the airways of patients with asthma compared with healthy individuals and in nasal polyp tissue from patients with CRSwNP compared with healthy sinus tissue or patients with CRS without NP. Tezepelumab binds specifically to TSLP, preventing its interaction with its heterodimeric receptor. Tezepelumab is currently under Phase III clinical trials to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. This trial is based on positive results of tezepelumab from the PATHWAY and NAVIGATOR trials in patients with severe, uncontrolled asthma and comorbid nasal polyps.

 

• Depemokimab/GSK3511294: GlaxoSmithKline

Depemokimab/GSK3511294, which GSK is developing to treat CRSwNP, is a humanized anti-interleukin (IL)-5 monoclonal antibody. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 is cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for diseases with higher levels of eosinophils. Depemokimab, with an extended half-life and improved IL-5 affinity compared to other approved therapies, is being studied by GSK in Phase III to evaluate the efficacy and safety of depemokimab in participants with CRSwNP.

 

Get In-Depth Knowledge on Chronic Rhinosinusitis with Nasal Polyps Market Trends and Forecasts with DelveInsight @ Chronic Rhinosinusitis with Nasal Polyps Treatment Market

 

Chronic Rhinosinusitis with Nasal Polyps Therapies and Key Companies

• NUCALA (mepolizumab): GlaxoSmithKline
• TEZSPIRE (tezepelumab): AstraZeneca/Amgen
• FASENRA (benralizumab): AstraZeneca
• Tezepelumab: AstraZeneca/Amgen
• CM310: Keymed Biosciences
• GSK3511294 (depemokimab): GlaxoSmithKline
• Omalizumab: Genentech, Inc
• Xolair: Novartis
• Verekitug (UPB-101): Upstream Bio Inc.
• Dupilumab SAR231893: Regeneron Pharmaceuticals
• GR1802 injection: Genrix (Shanghai) Biopharmaceutical
• SHR-1905 Injection: Guangdong Hengrui Pharmaceutical
• CM310: Keymed Biosciences Co.Ltd

 

Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Rhinosinusitis with Nasal Polyps Companies- AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis, Upstream Bio Inc., Regeneron Pharma, Genrix (Shanghai) Biopharmaceutical, Guangdong Hengrui Pharmaceutical, Keymed Biosciences Co.Ltd, and others
• Chronic Rhinosinusitis with Nasal Polyps Therapies- NUCALA (mepolizumab), TEZSPIRE (tezepelumab), FASENRA (benralizumab), Tezepelumab, CM310, GSK3511294 (depemokimab), Omalizumab, Xolair, Verekitug (UPB-101), Dupilumab SAR231893, GR1802 injection, SHR-1905 Injection, CM310, and others
• Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers
• Chronic Rhinosinusitis with Nasal Polyps Unmet Needs, KOL’s views, Analyst’s views, Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Rhinosinusitis with Nasal Polyps Market Report @ Chronic Rhinosinusitis with Nasal Polyps Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. CRSwNP Market Overview at a Glance

4. Epidemiology And Market Forecast Methodology

5. Executive Summary of CRSwNP

6. Key Events

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Emerging Drugs

12. CRSwNP: Market Analysis

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement and Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage